Heidi Greulich is an associated scientist at the Broad Institute of MIT and Harvard and lead scientist at the Dana-Farber Cancer Institute. She leads a group that studies mutations in genes that lead to cancer, with the goal of developing new cancer therapies. The principal focus of her research lies in examining the impact of somatic mutation on gene function and determining whether tumor cells depend on activity of a mutated gene for survival. Recent research directions include characterization of oncogenic mutations in the extracellular domain of the receptor tyrosine kinase, ERBB2, and novel oncogenic mutations in ARAF associated with a lung cancer patient response to sorafenib. Her main area of expertise is cancer biology with secondary expertise in cancer genomics.
Greulich earned a bachelor’s degree in molecular biology at Princeton University and a doctorate in molecular oncology at The Rockefeller University before undertaking a postdoctoral fellowship at Harvard University. She joined the Broad in 2004. She is the recipient of grants from Uniting Against Lung Cancer, Doctors Cancer Foundation, Lung Cancer Research Foundation, and the NIH Molecular Libraries Probe Production Centers Network.
Contact Heidi Greulich via email at firstname.lastname@example.org.Select Publications
Greulich H, Chen T-H, Feng W et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005; 2, e313.
Dutt A, Salvesen HB, Chen TH et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. USA. 2008; 105, 8713-8717.
Greulich H, Kaplan B, Mertins P et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. PNAS. 2012; 109, 14476-14481.
Imielinski M*, Greulich H*, Kaplan B et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J. Clin. Invest. 2014; 124, 1582-1586.
de Waal L, Lewis TA, Rees MG et al. Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics. Nature Chemical Biology, in press.
*These authors contributed equally.